Infertility in reproductive-age female cancer survivors

Cancer

Volumn 121, Issue 10, 2015, Pages 1532-1539

  Levine, Jennifer M ^a   Kelvin, Joanne Frankel ^b   Quinn, Gwendolyn P ^c   Gracia, Clarisa R ^d  

^a Department of Medicine   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

adolescent and young adult; cancer; fertility preservation; infertility

Indexed keywords

ANTINEOPLASTIC AGENT; FOLLITROPIN; GONADORELIN DERIVATIVE; GOSERELIN; ALKYLATING AGENT; GONADORELIN;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVOR; CRYOPRESERVATION; FEMALE FERTILITY; FEMALE GENITAL TRACT CANCER; FEMALE INFERTILITY; FERTILITY PRESERVATION; FOLLICULAR PHASE; GYNECOLOGIC SURGERY; HEALTH PROGRAM; HUMAN; MEDICAL ETHICS; OOCYTE; OVARIAN PRESERVATION; OVARIAN RESERVE; OVARIAN TRANSPOSITION; OVARY INSUFFICIENCY; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; REVIEW; RISK ASSESSMENT; SOCIAL PSYCHOLOGY; ADOLESCENT; ADULT; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; CHILD; COMPLICATION; CONSERVATIVE TREATMENT; DRUG EFFECTS; EARLY MENOPAUSE; ECONOMICS; FEMALE; INFERTILITY; INFERTILITY, FEMALE; INFERTILITY, MALE; INTERDISCIPLINARY COMMUNICATION; MALE; NEOPLASMS; OOCYTE RETRIEVAL; OVARY; PRESCHOOL CHILD; PROCEDURES; PROGRAM DEVELOPMENT; QUALITY OF LIFE; RADIATION RESPONSE; RADIOTHERAPY; SPERM RETRIEVAL; STANDARDS; STATISTICS AND NUMERICAL DATA; SURVIVOR; TRENDS; UNCERTAINTY;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; CHILD; CHILD, PRESCHOOL; CRYOPRESERVATION; FEMALE; FERTILITY PRESERVATION; GONADOTROPIN-RELEASING HORMONE; HUMANS; INFERTILITY; INFERTILITY, FEMALE; INFERTILITY, MALE; INTERDISCIPLINARY COMMUNICATION; MALE; MENOPAUSE, PREMATURE; NEOPLASMS; OOCYTE RETRIEVAL; ORGAN SPARING TREATMENTS; OVARY; PROGRAM DEVELOPMENT; QUALITY OF LIFE; RADIOTHERAPY; RISK ASSESSMENT; SPERM RETRIEVAL; SURVIVORS; UNCERTAINTY;

EID: 84929045162     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29181     Document Type: Review

References (68)

1. Coccia PF, Pappo AS, Altman J, et al. Adolescent and young adult oncology, version 2.2014. J Natl Compr Canc Netw. 2014; 12: 21-32.
2. Rowan K,. Fertility preservation during treatment is a growing issue for women. J Natl Cancer Inst. 2010; 102: 294-296.
3. Loren AW, Mangu PB, Beck LN, et al. American Society of Clinical Oncology. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013; 31: 2500-2510.
4. Practice Committee of American Society for Reproductive Medicine. Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. Fertil Steril. 2013; 100: 1214-1223.
5. Goodwin T, Elizabeth Oosterhuis B, Kiernan M, Hudson MM, Dahl GV,. Attitudes and practices of pediatric oncology providers regarding fertility issues. Pediatr Blood Cancer. 2007; 48: 80-85.
6. Quinn GP, Vadaparampil ST, Lee JH, et al. Physician referral for fertility preservation in oncology patients: a national study of practice behaviors. J Clin Oncol. 2009; 27: 5952-5957.
7. Johnston RJ, Wallace WH,. Normal ovarian function and assessment of ovarian reserve in the survivor of childhood cancer. Pediatr Blood Cancer. 2009; 53: 296-302.
8. Gracia CR, Sammel MD, Freeman E, et al. Impact of cancer therapies on ovarian reserve. Fertil Steril. 2012; 97: 134-140.
9. Critchley HO, Wallace WH,. Impact of cancer treatment on uterine function. J Natl Cancer Inst Monogr. 2005; 2005: 64-68.
10. Littley MD, Shalet SM, Beardwell CG, Ahmed SR, Applegate G, Sutton ML,. Hypopituitarism following external radiotherapy for pituitary tumours in adults. Q J Med. 1989; 70: 145-160.
11. Su HI, Sammel MD, Velders L, et al. Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors. Fertil Steril. 2010; 94: 645-654.
12. van Dorp W, van den Heuvel-Eibrink MM, Stolk L, et al. Genetic variation may modify ovarian reserve in female childhood cancer survivors. Hum Reprod. 2013; 28: 1069-1076.
13. von Wolff M, Thaler CJ, Frambach T, et al. Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase. Fertil Steril. 2009; 92: 1360-1365.
14. von Wolff M, Montag M, Dittrich R, Denschlag D, Nawroth F, Lawrenz B,. Fertility preservation in women-a practical guide to preservation techniques and therapeutic strategies in breast cancer, Hodgkin's lymphoma and borderline ovarian tumours by the fertility preservation network FertiPROTEKT. Arch Gynecol Obstet. 2011; 284: 427-435.
15. Madrigrano A, Westphal L, Wapnir I,. Egg retrieval with cryopreservation does not delay breast cancer treatment. Am J Surg. 2007; 194: 477-481.
16. Levenseller BL, Soucier DJ, Miller VA, Harris D, Conway L, Bernhardt BA,. Stakeholders' opinions on the implementation of pediatric whole exome sequencing: implications for informed consent. J Genet Couns. 2014; 23: 552-565.
17. Parmegiani L, Cognigni GE, Bernardi S, et al. Efficiency of aseptic open vitrification and hermetical cryostorage of human oocytes. Reprod Biomed Online. 2011; 23: 505-512.
18. Cobo A, Meseguer M, Remohi J, Pellicer A,. Use of cryo-banked oocytes in an ovum donation programme: a prospective, randomized, controlled, clinical trial. Hum Reprod. 2010; 25: 2239-2246.
19. Cil AP, Bang H, Oktay K,. Age-specific probability of live birth with oocyte cryopreservation: an individual patient data meta-analysis. Fertil Steril. 2013; 100: 492-499.
20. Practice Committee of the American Society for Reproductive Medicine. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril. 2012; 98: 1407-1415.
21. Domingo J, Guillen V, Ayllon Y, et al. Ovarian response to controlled ovarian hyperstimulation in cancer patients is diminished even before oncological treatment. Fertil Steril. 2012; 97: 930-934.
22. Friedler S, Koc O, Gidoni Y, Raziel A, Ron-El R,. Ovarian response to stimulation for fertility preservation in women with malignant disease: a systematic review and meta-analysis. Fertil Steril. 2012; 97: 125-133.
23. Oktay K,. Further evidence on the safety and success of ovarian stimulation with letrozole and tamoxifen in breast cancer patients undergoing in vitro fertilization to cryopreserve their embryos for fertility preservation. J Clin Oncol. 2005; 23: 3858-3859.
24. Oktay K, Hourvitz A, Sahin G, et al. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J Clin Endocrinol Metab. 2006; 91: 3885-3890.
25. Azim AA, Costantini-Ferrando M, Oktay K,. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol. 2008; 26: 2630-2635.
26. Practice Committee of American Society for Reproductive Medicine. Ovarian hyperstimulation syndrome. Fertil Steril. 2008; 90: S188-S193.
27. Practice Committees of the American Society for Reproductive Medicine, Society for Assisted Reproductive Technology. In vitro maturation: a committee opinion. Fertil Steril. 2013; 99: 663-666.
28. Prasath EB, Chan ML, Wong WH, et al. First pregnancy and live birth resulting from cryopreserved embryos obtained from in vitro matured oocytes after oophorectomy in an ovarian cancer patient. Hum Reprod. 2014; 29: 276-278.
29. Donnez J, Dolmans MM,. Fertility preservation in women. Nat Rev Endocrinol. 2013; 9: 735-749.
30. Bastings L, Beerendonk CC, Westphal JR, et al. Autotransplantation of cryopreserved ovarian tissue in cancer survivors and the risk of reintroducing malignancy: a systematic review. Hum Reprod Update. 2013; 19: 483-506.
31. Smitz J, Dolmans MM, Donnez J, et al. Current achievements and future research directions in ovarian tissue culture, in vitro follicle development and transplantation: implications for fertility preservation. Hum Reprod Update. 2010; 16: 395-414.
32. Haie-Meder C, Mlika-Cabanne N, Michel G, et al. Radiotherapy after ovarian transposition: ovarian function and fertility preservation. Int J Radiat Oncol Biol Phys. 1993; 25: 419-424.
33. Ben-Aharon I, Gafter-Gvili A, Leibovici L, Stemmer SM,. Pharmacological interventions for fertility preservation during chemotherapy: a systematic review and meta-analysis. Breast Cancer Res Treat. 2010; 122: 803-811.
34. Gerber B, von Minckwitz G, Stehle H, et al. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol. 2011; 29: 2334-2341.
35. Bedaiwy MA, Abou-Setta AM, Desai N, et al. Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: a systematic review and meta-analysis. Fertil Steril. 2011; 95: 906-914.
36. Peres J,. New hope for young breast cancer patients. JNCI. 2014; 106 (9).
37. Park JY, Kim DY, Suh DS, et al. Reproductive outcomes after laparoscopic radical trachelectomy for early-stage cervical cancer. J Gynecol Oncol. 2014; 25: 9-13.
38. Tinelli R, Malzoni M, Cosentino F, et al. Feasibility, safety, and efficacy of conservative laparoscopic treatment of borderline ovarian tumors. Fertil Steril. 2009; 92: 736-741.
39. Gotlieb WH, Beiner ME, Shalmon B, et al. Outcome of fertility-sparing treatment with progestins in young patients with endometrial cancer. Obstet Gynecol. 2003; 102: 718-725.
40. Anderson RA, Cameron DA,. Pretreatment serum anti-Mullerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. J Clin Endocrinol Metab. 2011; 96: 1336-1343.
41. Dillon KE, Sammel MD, Prewitt M, et al. Pretreatment antimullerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy. Fertil Steril. 2013; 99: 477-483.
42. Partridge AH, Ruddy KJ, Gelber S, et al. Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. Fertil Steril. 2010; 94: 638-644.
43. Bastings L, Baysal O, Beerendonk CC, et al. Deciding about fertility preservation after specialist counselling. Hum Reprod. 2014; 29: 1721-1729.
44. Wilkes S, Coulson S, Crosland A, Rubin G, Stewart J,. Experience of fertility preservation among younger people diagnosed with cancer. Hum Fertil (Camb). 2010; 13: 151-158.
45. Jeruss JS, Woodruff TK,. Preservation of fertility in patients with cancer. N Engl J Med. 2009; 360: 902-911.
46. Tschudin S, Bitzer J,. Psychological aspects of fertility preservation in men and women affected by cancer and other life-threatening diseases. Hum Reprod Update. 2009; 15: 587-597.
47. Ayensu-Coker L, Essig E, Breech LL, Lindheim S,. Ethical quandaries in gamete-embryo cryopreservation related to oncofertility. J Law Med Ethics. 2013; 41: 711-719.
48. Ethics Committee of American Society for Reproductive Medicine. Fertility preservation and reproduction in patients facing gonadotoxic therapies: a committee opinion. Fertil Steril. 2013; 100: 1224-1231.
49. Barcroft J, Dayoub N, Thong KJ,. Fifteen year follow-up of embryos cryopreserved in cancer patients for fertility preservation. J Assist Reprod Genet. 2013; 30: 1407-1413.
50. Hill GA, Freeman MR,. Embryo disposition: choices made by patients and donor oocyte recipients. Fertil Steril. 2011; 95: 940-943.
51. McMahon CA, Saunders DM,. Attitudes of couples with stored frozen embryos toward conditional embryo donation. Fertil Steril. 2009; 91: 140-147.
52. Hirshfeld-Cytron J, Grobman WA, Milad MP,. Fertility preservation for social indications: a cost-based decision analysis. Fertil Steril. 2012; 97: 665-670.
53. Basco D, Campo-Engelstein L, Rodriguez S,. Insuring against infertility: expanding state infertility mandates to include fertility preservation technology for cancer patients. J Law Med Ethics. 2010; 38: 832-839.
54. Pennings G, de Wert G, Shenfield F, Cohen J, Tarlatzis B, Devroey P,; ESHRE Task Force on Ethics and Law. ESHRE Task Force on Ethics and Law 14: equity of access to assisted reproductive technology. Hum Reprod. 2008; 23: 772-774.
55. Goodman LR, Balthazar U, Kim J, Mersereau JE,. Trends of socioeconomic disparities in referral patterns for fertility preservation consultation. Hum Reprod. 2012; 27: 2076-2081.
56. Letourneau JM, Smith JF, Ebbel EE, et al. Racial, socioeconomic, and demographic disparities in access to fertility preservation in young women diagnosed with cancer. Cancer. 2012; 118: 4579-4588.
57. Mersereau JE, Goodman LR, Deal AM, Gorman JR, Whitcomb BW, Su HI,. To preserve or not to preserve: how difficult is the decision about fertility preservation? Cancer. 2013; 119: 4044-4050.
58. http://blog.oncofertility.northwestern.edu/2013/06/support-for-fertility-preservation-is-now-an-ama-policy/. Accessed July 12, 2014.
59. Kim J, Kim KH, Mersereau JE,. Building a successful fertility preservation program at a major cancer center. J Gynecol Oncol. 2014; 25: 148-154.
60. Clayman ML, Harper MM, Quinn GP, Reinecke J, Shah S,. Oncofertility resources at NCI-designated comprehensive cancer centers. J Natl Compr Canc Netw. 2013; 11: 1504-1509.
61. Kelvin JF, Reinecke J,. Institutional approaches to implementing fertility preservation for cancer patients. Adv Exp Med Biol. 2012; 732: 165-173.
62. Quinn GP, Vadaparampil ST, Gwede CK, Reinecke JD, Mason TM, Silva C,. Developing a referral system for fertility preservation among patients with newly diagnosed cancer. J Natl Compr Canc Netw. 2011; 9: 1219-1225.
63. Flemming F,. Nicole's oncofertility toolkit. http://www.accc-cancer.org/oncology-issues/articles/MayJune2012/Nicole 's-Oncofertility-Toolkit.pdf. Accessed July 24, 2014.
64. Livestrong Foundation. How cancer centers can create a system for addressing fertility. http://www.livestrong.org/we-can-help/fertility-services/how-cancer-centers-can-create-a-system-for-addressing-fertility/. Accessed July 24, 2014.
65. Reinecke JD, Kelvin JF, Arvey SR, et al. Implementing a systematic approach to meeting patients' cancer and fertility needs: a review of the Fertile Hope Centers of Excellence program. J Oncol Pract. 2012; 8: 303-308.
66. Smith K, Efymow, B, Gracia C,. Patient navigation and coordination of care for the oncofertility patient: a practical guide. In:, Gracia C, Woodruff TK, eds. Oncofertility Medical Practice: Clinical Issues and Implementation. New York, NY: Springer Science+Business Media; 2012: 175.
67. Oncofertility Consortium. Implementation of a fertility preservation program. http://oncofertility.northwestern.edu/implementation-fertility-preservation-program. Accessed July 25, 2014.
68. Committee IP, Kim SS, Donnez J, et al. Recommendations for fertility preservation in patients with lymphoma, leukemia, and breast cancer. J Assist Reprod Genet. 2012; 29: 465-468.